PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26056729-11 2015 Moreover, the association of VF factor with 148 Asp/Glu of APE1 genotype distribution and POAG progression (OR 2.25; 95% CI 1.30-3.89) was also found. Aspartic Acid 48-51 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 59-63 17922186-6 2008 For homozygous carriers of the Glu allele in APEX1, a significant protective effect was found when compared to Asp/Asp carriers (odds ratio (OR) = 0.60, 95% confidence interval (CI) = 0.38-0.94). Aspartic Acid 111-114 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 45-50 25038572-9 2014 The analysis of the model structure of N212D APE1 provides evidence for alternate hydrogen bonding between Asn-212 and Asp-210 residues, whereas N212A possesses an extended active site pocket due to Asn removal. Aspartic Acid 119-122 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 45-49 23369758-4 2013 We found that a significantly increased risk of vitiligo was associated with the APE1 Asp/Glu (adjusted odds ratio (OR) 1.24; 95% confidence interval (CI) 1.02-1.52) and Glu/Glu genotypes (adjusted OR 1.48; 95% CI 1.13-1.93), compared with the APE1 Asp/Asp genotype, whereas no vitiligo risk was associated with the genotypes ADPRT-Val762Ala and XRCC1-Arg399Gln. Aspartic Acid 86-89 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 81-85 23369758-4 2013 We found that a significantly increased risk of vitiligo was associated with the APE1 Asp/Glu (adjusted odds ratio (OR) 1.24; 95% confidence interval (CI) 1.02-1.52) and Glu/Glu genotypes (adjusted OR 1.48; 95% CI 1.13-1.93), compared with the APE1 Asp/Asp genotype, whereas no vitiligo risk was associated with the genotypes ADPRT-Val762Ala and XRCC1-Arg399Gln. Aspartic Acid 249-252 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 81-85 23369758-4 2013 We found that a significantly increased risk of vitiligo was associated with the APE1 Asp/Glu (adjusted odds ratio (OR) 1.24; 95% confidence interval (CI) 1.02-1.52) and Glu/Glu genotypes (adjusted OR 1.48; 95% CI 1.13-1.93), compared with the APE1 Asp/Asp genotype, whereas no vitiligo risk was associated with the genotypes ADPRT-Val762Ala and XRCC1-Arg399Gln. Aspartic Acid 249-252 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 81-85 23369758-5 2013 Furthermore, serum 8-OHdG levels were elevated in the APE1-148Glu allele carriers (Asp/Glu+Glu/Glu), in an allele dose-response manner, with the risk of vitiligo (Ptrend<0.05). Aspartic Acid 83-86 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 54-58 23038158-0 2012 The APE1 Asp/Asp genotype and the combination of APE1 Asp/Asp and hOGG1-Cys variants are associated with increased p53 mutation in non-small cell lung cancer. Aspartic Acid 9-12 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 4-8 23038158-9 2012 However, a higher risk of p53 mutation was found in participants with the APE1 Asp/Asp genotype than in those with the APE1-Glu allele (OR, 2.15; 95% CI, 1.19-3.87; P = 0.011). Aspartic Acid 79-82 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 74-78 23038158-9 2012 However, a higher risk of p53 mutation was found in participants with the APE1 Asp/Asp genotype than in those with the APE1-Glu allele (OR, 2.15; 95% CI, 1.19-3.87; P = 0.011). Aspartic Acid 83-86 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 74-78 23038158-10 2012 The risk of p53 mutation was also higher in participants with APE1 Asp/Asp plus hOGG1-Cys than in those with APE1-Glu plus hOGG1 Ser/Ser (OR, 3.72; 95% CI, 1.33-10.40; P = 0.012). Aspartic Acid 67-70 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 62-66 23038158-10 2012 The risk of p53 mutation was also higher in participants with APE1 Asp/Asp plus hOGG1-Cys than in those with APE1-Glu plus hOGG1 Ser/Ser (OR, 3.72; 95% CI, 1.33-10.40; P = 0.012). Aspartic Acid 71-74 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 62-66 22184996-2 2011 The frequency of chromosome aberrations was found to be significantly lower in the carriers of the genotype hOGG1 326 Ser/Ser (versus the variant Ser/Cys), APE1 148 Asp/Asp (versus Val/Ala and Ala/Ala). Aspartic Acid 165-168 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 156-160 19181704-7 2009 D70 of APE1 aligns with A138 of LMAP and mutation of the latter to aspartate significantly reduces its 3"-phosphodiesterase activity. Aspartic Acid 67-76 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 7-11 25024628-8 2014 RESULTS: The APE1 148 Glu/Glu genotype was significantly associated with an increased risk of colorectal cancer (OR = 2.411, 95%CI: 1.497-3.886, P < 0.001 relative to Asp/Asp genotype). Aspartic Acid 170-173 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 13-17 25024628-8 2014 RESULTS: The APE1 148 Glu/Glu genotype was significantly associated with an increased risk of colorectal cancer (OR = 2.411, 95%CI: 1.497-3.886, P < 0.001 relative to Asp/Asp genotype). Aspartic Acid 174-177 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 13-17 24375045-0 2013 The role of the 148 Asp/Glu polymorphism of the APE1 gene in the development and progression of primary open angle glaucoma development in the Polish population. Aspartic Acid 20-23 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 48-52 23038158-11 2012 CONCLUSIONS: These results suggest that the APE1 Asp/Asp genotype and the combination of the APE1 Asp/Asp and hOGG1-Cys variants are associated with increased risk of p53 mutation in non-small cell lung cancer. Aspartic Acid 49-52 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 44-48 23038158-11 2012 CONCLUSIONS: These results suggest that the APE1 Asp/Asp genotype and the combination of the APE1 Asp/Asp and hOGG1-Cys variants are associated with increased risk of p53 mutation in non-small cell lung cancer. Aspartic Acid 53-56 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 44-48 23038158-11 2012 CONCLUSIONS: These results suggest that the APE1 Asp/Asp genotype and the combination of the APE1 Asp/Asp and hOGG1-Cys variants are associated with increased risk of p53 mutation in non-small cell lung cancer. Aspartic Acid 53-56 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 44-48 23038158-11 2012 CONCLUSIONS: These results suggest that the APE1 Asp/Asp genotype and the combination of the APE1 Asp/Asp and hOGG1-Cys variants are associated with increased risk of p53 mutation in non-small cell lung cancer. Aspartic Acid 53-56 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 44-48 21864556-5 2011 As for APE1 Asp148Glu, heterozygous subjects showed significantly higher urinary 8-OHdG concentrations than did those homozygous for Asp/Asp. Aspartic Acid 12-15 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 7-11 19528510-4 2009 RESULTS: Individuals carrying the APE1 Asp148Glu heterozygous and homozygous variant genotype had a 3.23-fold increased risk of lung cancer compared with these carrying the wild-type (Asp/Asp) genotype (p<0.0001), and those carrying the 148Glu homozygous genotype had a 3.17-fold increased risk (p=0.023). Aspartic Acid 39-42 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 34-38 19528510-4 2009 RESULTS: Individuals carrying the APE1 Asp148Glu heterozygous and homozygous variant genotype had a 3.23-fold increased risk of lung cancer compared with these carrying the wild-type (Asp/Asp) genotype (p<0.0001), and those carrying the 148Glu homozygous genotype had a 3.17-fold increased risk (p=0.023). Aspartic Acid 184-187 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 34-38 17922186-6 2008 For homozygous carriers of the Glu allele in APEX1, a significant protective effect was found when compared to Asp/Asp carriers (odds ratio (OR) = 0.60, 95% confidence interval (CI) = 0.38-0.94). Aspartic Acid 115-118 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 45-50 17531525-4 2007 A significant association between the APE1 Asp148Glu polymorphism and lung cancer risk was found, with adjusted odds ratios (OR) of 3.38 (p=0.001) for the Asp/Glu genotype and 2.39 (p=0.038) for the Glu/Glu genotype. Aspartic Acid 43-46 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 38-42 18503157-0 2008 Association of genetic polymorphism of the DNA base excision repair gene (APE-1 Asp/148 Glu) and HPV type (16/18) with the risk of cervix cancer in north Indian population. Aspartic Acid 80-83 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 74-79 18503157-5 2008 The purpose of the present study was, therefore to investigate APE-1 genotypes (Asp/Asp, Asp/Glu, Glu/Glu) with different histological subtypes in cases compared with controls. Aspartic Acid 80-83 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 63-68 18503157-5 2008 The purpose of the present study was, therefore to investigate APE-1 genotypes (Asp/Asp, Asp/Glu, Glu/Glu) with different histological subtypes in cases compared with controls. Aspartic Acid 84-87 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 63-68 18503157-5 2008 The purpose of the present study was, therefore to investigate APE-1 genotypes (Asp/Asp, Asp/Glu, Glu/Glu) with different histological subtypes in cases compared with controls. Aspartic Acid 84-87 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 63-68 18505345-12 2008 The lowest residual DNA damage level was determined in subjects with the combined APE1(Asp/Asp)/hOGG1(Ser/Cys+Cys/Cys) genotypes. Aspartic Acid 87-90 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 82-86 18053222-9 2007 APE1 148 glu/glu + asp/glu genotype was associated with a decrease in logged 8-OHdG of 0.40 (95%CI -0.73, -0.07) compared to APE1 148 asp/asp. Aspartic Acid 19-22 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 0-4 16406883-7 2006 When APE1 and XRCC1 polymorphisms were evaluated together, we found an increased risk of the XRCC1(399Arg/Gln+Gln/Gln)/APE1(51Gln/Gln) (OR 4.0, 95% CI 1.3 to 12.5) and XRCC1(399Arg/Gln+Gln/Gln)/APE1(148Asp/Asp) (OR 2.9, 95% CI 1.4 to 6.1) genotypes in white men. Aspartic Acid 202-205 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 5-9 17555083-5 2007 RESULTS: The frequencies of the Asp and Glu alleles of APE1 148 in our study population were 61% and 39%, respectively. Aspartic Acid 32-35 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 55-59 17259346-4 2007 This mutant form of APE1, termed ED, possesses two amino acid substitutions at active site residues Glu(96) (changed to Gln) and Asp(210) (changed to Asn). Aspartic Acid 129-132 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 20-24 16406883-7 2006 When APE1 and XRCC1 polymorphisms were evaluated together, we found an increased risk of the XRCC1(399Arg/Gln+Gln/Gln)/APE1(51Gln/Gln) (OR 4.0, 95% CI 1.3 to 12.5) and XRCC1(399Arg/Gln+Gln/Gln)/APE1(148Asp/Asp) (OR 2.9, 95% CI 1.4 to 6.1) genotypes in white men. Aspartic Acid 202-205 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 119-123 16406883-7 2006 When APE1 and XRCC1 polymorphisms were evaluated together, we found an increased risk of the XRCC1(399Arg/Gln+Gln/Gln)/APE1(51Gln/Gln) (OR 4.0, 95% CI 1.3 to 12.5) and XRCC1(399Arg/Gln+Gln/Gln)/APE1(148Asp/Asp) (OR 2.9, 95% CI 1.4 to 6.1) genotypes in white men. Aspartic Acid 202-205 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 119-123 10871340-0 2000 Substitution of Asp-210 in HAP1 (APE/Ref-1) eliminates endonuclease activity but stabilises substrate binding. Aspartic Acid 16-19 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 33-36 15858043-2 2005 Among these residues, aspartate 92 and histidine 117 are both required for Fv1(b) resistance, whereas the latter is sufficient to confer Ref1 resistance. Aspartic Acid 22-31 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 137-141 15044328-5 2004 The adjusted odds ratio for the current smokers with APE1 148Asp/Asp, Asp/Glu and Glu/Glu genotype as compared with the never smokers with the Asp/Asp genotype were 3.01 (95% CI 1.39-6.51, P = 0.005), 2.73 (95% CI 1.29-5.77, P = 0.008) and 7.33 (95% CI 2.93-18.3, P < 0.001), respectively. Aspartic Acid 61-64 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 53-57 15044328-5 2004 The adjusted odds ratio for the current smokers with APE1 148Asp/Asp, Asp/Glu and Glu/Glu genotype as compared with the never smokers with the Asp/Asp genotype were 3.01 (95% CI 1.39-6.51, P = 0.005), 2.73 (95% CI 1.29-5.77, P = 0.008) and 7.33 (95% CI 2.93-18.3, P < 0.001), respectively. Aspartic Acid 65-68 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 53-57 15044328-5 2004 The adjusted odds ratio for the current smokers with APE1 148Asp/Asp, Asp/Glu and Glu/Glu genotype as compared with the never smokers with the Asp/Asp genotype were 3.01 (95% CI 1.39-6.51, P = 0.005), 2.73 (95% CI 1.29-5.77, P = 0.008) and 7.33 (95% CI 2.93-18.3, P < 0.001), respectively. Aspartic Acid 65-68 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 53-57 15044328-5 2004 The adjusted odds ratio for the current smokers with APE1 148Asp/Asp, Asp/Glu and Glu/Glu genotype as compared with the never smokers with the Asp/Asp genotype were 3.01 (95% CI 1.39-6.51, P = 0.005), 2.73 (95% CI 1.29-5.77, P = 0.008) and 7.33 (95% CI 2.93-18.3, P < 0.001), respectively. Aspartic Acid 65-68 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 53-57 12758078-0 2003 Investigation of the role of the histidine-aspartate pair in the human exonuclease III-like abasic endonuclease, Ape1. Aspartic Acid 43-52 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 113-117 12758078-4 2003 Here, we apply liquid-state NMR to investigate the role of a critical histidine residue of apurinic endonuclease 1 (Ape1), a human DNA repair enzyme that cleaves adjacent to abasic sites in DNA using one or more divalent cations and an active-site His-Asp pair. Aspartic Acid 252-255 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 91-114 12758078-4 2003 Here, we apply liquid-state NMR to investigate the role of a critical histidine residue of apurinic endonuclease 1 (Ape1), a human DNA repair enzyme that cleaves adjacent to abasic sites in DNA using one or more divalent cations and an active-site His-Asp pair. Aspartic Acid 252-255 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 116-120 12758078-5 2003 The results of these studies suggest that the Ape1 His-Asp pair does not function as either a general base catalyst or a metal ligand. Aspartic Acid 55-58 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 46-50 15084314-5 2004 Similar to its action on AP sites in ds DNA, catalysis of endonucleolytic cleavage of ss DNA by APE1 is Mg(2+) dependent, DNA N-glycosylase independent, and requires an active site aspartate. Aspartic Acid 181-190 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 96-100 10871340-0 2000 Substitution of Asp-210 in HAP1 (APE/Ref-1) eliminates endonuclease activity but stabilises substrate binding. Aspartic Acid 16-19 apurinic/apyrimidinic endodeoxyribonuclease 1 Homo sapiens 37-42